A turning point is approaching in the rapidly growing market for weight loss medications. The Danish pharmaceutical giant, Novo Nordisk<\/b>, has launched daily Wegovy<\/b> pills in the US. This marks the first time patients can take a GLP-1<\/b> class medication in oral form instead of via injection.<\/p>\n
Analysts predict that 2026<\/b> will be a breakthrough year for the industry, as easy-to-use tablets make treatment more accessible. The new medication has already shown record-breaking results in the US; by the end of January, 50,000 prescriptions<\/b> were being issued per week. This figure even surpasses the launch phase of the injectable version of Wegovy. Experts estimate that the sector’s value will reach $200 billion by 2030<\/b>.<\/p>\n
The drug\u2019s popularity is driven by several key factors:<\/p>\n
Ease of use:<\/b> Tablets are far simpler for those with a fear of needles.<\/p>\n<\/li>\n Storage:<\/b> Unlike injections, tablets do not require refrigeration.<\/p>\n<\/li>\n Cost-effectiveness:<\/b> The price of the pills ranges from $149 to $299 per month<\/b>.<\/p>\n<\/li>\n<\/ul>\n While the tablet is slightly less effective than the injectable version, it remains a strong alternative for individuals struggling with obesity.<\/p>\n The obesity crisis is reaching global proportions. Projections suggest that by 2050<\/b>, more than half of the world’s adult population will be overweight, leading to a sharp increase in demand for weight loss drugs.<\/p>\n In the US, one in eight adults<\/b> has already used or is currently using such medications. In the UK, the number of users has reached 1.6 million<\/b>, with women outnumbering men two to one.<\/p>\n According to statistical data, obesity prevalence in the US varies significantly across ethnic groups:<\/p>\nGlobal Trends and Demographics<\/h3>\n